BRCA1/2-associated breast cancers are sensitive to poly(ADPribose) polymerase (PARP) inhibitors and platinum compounds mainly due to their deficiency in DNA repair via homologous recombination (HR). However, approximately only 15% of triple-negative breast cancers (TNBCs) are BRCA1/2-associated. TNBCs that exhibit BRCAness (a phenotype reflecting impaired HR in BRCA1/2-negative tumors) are also regarded sensitive to PARP inhibitors and platinum compounds. Thus, we hypothesized that hereditary BRCA1/2-negative TNBCs may exhibit BRCAness. To find a subset of hereditary BRCA1/2-negative TNBCs among 360 TNBCs, we first identified a group of 41 hereditary TNBCs by analyzing the family histories of the patients. Next, we tested this group for the presence of germline BRCA1/2 mutations, and finally, we compared the expression levels of 120 genes involved in HR and five other major mechanisms of DNA damage repair between BRCA1/2-associated and BRCA1/2-negative subgroups of hereditary TNBCs using real-time PCR arrays. Approximately 73% of the hereditary TNBCs were BRCA1/2-associated and 27% were BRCA1/2-negative. The expression levels of the analyzed genes showed no significant differences between these two subgroups indicating the BRCAness of the BRCA1/2-negative hereditary TNBCs and thereby distinguishing a novel subset of TNBCs as a potential target for PARP inhibitors or platinum-based therapy. The results show the significance of family history in selecting patients with TNBC for therapies directed at incompetent DNA repair (e.g., PARP inhibitors and/or platinum-based therapies) and indicate that a relatively simple strategy for broadening the target group for these modes of treatment is to identify patients with hereditary TNBCs.
The successful treatment of breast cancer requires the precise selection of a target group of patients who are most likely to benefit from the applied therapy. Triple-negative breast cancers (TNBCs) account for 15-20% of all breast cancers. 1 Patients with TNBCs have a poor prognosis and a high risk of relapse. There is no targeted treatment for this subset of breast cancer due to lack of molecular targets for therapy. 2 TNBCs constitute 50-80% of the breast cancers in BRCA1 mutation carriers, 3, 4 and BRCA1-associated breast cancers are particularly sensitive to poly(ADPribose) polymerase (PARP) inhibitors 5 and DNA cross-linking agents, such as platinum-based compounds, 6 due to their deficiency in DNA repair via homologous recombination (HR) and nucleotide excision repair (NER). 7, 8 However, few TNBC patients can take advantage of the specificity of these therapies because depending on the age only 15-27% of patients with TNBCs carry germline mutations in BRCA1/ 2. 9-11 Therefore, to improve the treatment results for this group of patients, great effort has been recently directed toward defining subsets of TNBCs that may be sensitive to therapies that target incompetent or inefficient DNA repair in tumor cells. One way to achieve this goal is to search for germline mutations in genes other than BRCA1/2 that are involved in DNA repair through HR. It has been reported that TNBCs are enriched for defects in genes involved in HR. 12 We recently reported that approximately 3.8% of patients with TNBCs carried germline mutations in genes other than BRCA1/2 that are involved in DNA repair by HR. 9 Thus, identifying germline mutations in these other genes involved in DNA damage repair by HR will increase the proportion of TNBC patients who may benefit from PARP inhibitor and platinum drug therapies. However, the vast majority of TNBC patients would remain without effective targeted treatment.
Another strategy for expanding the target group for those treatment methods would be to identify TNBCs that exhibit so-called BRCAness. BRCAness refers to the phenotypic characteristics of sporadic tumors lacking BRCA1/2 germline mutations, particularly TNBCs, that exhibit defects in DNA repair via HR. 13 Identifying TNBCs with BRCAness would facilitate therapeutic decision-making for patients harboring these tumors because these tumors are expected to react to therapy similarly to BRCA1-associated breast cancers, with sensitivity to platinum compounds or PARP inhibitors. 13 Indeed, approximately five clinical trials for breast, ovarian, pancreatic and prostate cancer patients (http://clinicaltrials. gov) have already been based on this assumption. The BRCAness phenotype has been correlated with alterations in the mechanisms of DNA repair, and the definition of BRCAness is centered only on deficient HR. However, several reports have indicated that the BRCAness phenotype is more complex because the BRCA1 gene is also involved in other DNA damage repair mechanisms that may be relevant (reviewed in Refs. 13 and 14) . Therefore, because multiple genes are involved in the HR pathway and even more are involved in these other major DNA damage repair pathways, 15 we considered BRCA1/2-negative tumors with a similar profile of expression of DNA damage repair genes as that of BRCA1/2-associated breast cancers to have BRCAness in the present study.
An estimated 5-10% of all breast cancers are associated with hereditary risk. 16 Familial aggregation of breast cancer in women below age 51 years is mainly due to heritable causes. 17 Germline mutations in the BRCA1/2 genes are found in approximately 30% of patients with the family risk. 16 However, the status of HR and other DNA repair pathways in the tumor cells of the remaining vast majority of hereditary breast cancers, particularly hereditary TNBCs, is unknown. This study tested the hypothesis that hereditary BRCA1/2-negative TNBCs exhibit BRCAness and therefore may be sensitive to PARP inhibitors and platinum compounds. To this end, using real-time PCR arrays, we compared the expression levels of 120 genes representing HR and five main mechanisms of DNA damage repair between a group of BRCA1/2-associated hereditary TNBCs and a group of BRCA1/2-negative hereditary TNBCs.
Material and Methods

Patients and study design
Altogether, 384 consecutive patients from the cancer registry of the International Hereditary Cancer Center in Szczecin, who were unselected for a family history of cancer, and were diagnosed with TNBC from 2002 to 2014 were studied. Patients were eligible for the study if they had a new diagnosis of a clinical Stage I-III invasive triple-negative breast cancer. A detailed family history concerning cancers in relatives was available for 93.8% (360/384) of the initial cohort. A family history was established either by constructing a family tree or by completing a standardized questionnaire.
Patients with breast cancer and a history of breast cancer and/or ovarian cancer at any age of diagnosis in at least two close blood relatives were classified as having hereditary TNBC. 18 Close blood relatives include first-, second-, and third-degree relatives. 19 Patients with hereditary TNBCs were genotyped to determine the presence of BRCA1/2 germline mutations, and the expression levels of DNA repair genes in the tumor tissue were assessed. After tumor RNA quality assessment, four cases were excluded, leaving 37 eligible cases for comparison of the expression of DNA repair genes between BRCA1/2-associated and BRCA1/2-negative subgroups. Based on a literature review, we selected 120 DNA repair genes with documented roles in the following DNA repair pathways: HR, NER, base excision repair-BER, nonhomologous end joining -NHEJ, mismatch repair -MMR, and the Fanconi anemia pathway-FAP. Special attention was paid to genes described as being associated with sensitivity to PARP inhibition. [20] [21] [22] [23] A flow diagram of the patient selection process used in this study is shown in Figure 1a .
A pathology review and an immunohistochemical analysis were conducted as described previously. 3 The study was approved by the Research Ethics Review Board of the Pomeranian Medical University.
Genetic testing
All eligible patients with Stage I-III TNBC were approached for genetic testing just after diagnosis and the acceptance rate was 81% (384/458). Genomic DNA was prepared from 5-10 ml of peripheral blood leukocytes. We genotyped the pathogenic variants in the BRCA1/2 genes that have been
What's new?
Triple-negative breast cancers (TNBCs) that are positive for BRCA1/2 mutations display impairments in DNA repair via homologous recombination (HR), rendering the tumors sensitive to poly(ADPribose) polymerase (PARP) inhibitors and DNA crosslinking drugs. Only a minority of TNBC patients, however, carry germline BRCA1/2 aberrations. In the present study, 27% of hereditary TNBCs examined were found to be BRCA1/2-negative, yet showed no significant differences in the expression of HR-related genes or other DNA damage repair genes when compared with BRCA1/2-associated tumors. The BRCAness phenomenon distinguishes a subset of BRCA1/2-negative hereditary TNBCs, which may be susceptible to PARP inhibitors and platinum-based therapies.
described in the Polish population, including founder mutations and other rare mutations, as described previously. 9 The entire coding regions of BRCA1/2 of patients with hereditary TNBCs who were negative for germline BRCA1/2 recurrent mutations were additionally sequenced using direct or nextgeneration sequencing. Finally, patients lacking BRCA1/2 mutations were screened for large genomic rearrangements in the BRCA1/2 genes by multiplex ligation-dependent probe amplification using SALSA P002-C1 BRCA1 and SALSA P045-B2 BRCA2 MLPA kits (MRC-Holland, Amsterdam, Holland) to detect large genomic deletions or duplications. PCR products were separated on an ABI 3130 Genetic Analyzer (Applied Biosystems, Waltham, MA). Variations in the peak areas were evaluated by comparing each sample to a normal control.
RNA isolation
Three to five serial 7-lm-thick sections were cut from each tumor tissue fixed in 10% neutral buffered formalin and embedded in paraffin (FFPE). The tumor area was manually microdissected by a pathologist under a light microscope. Total RNA was extracted using the RNeasy FFPE Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The concentration of total RNA (ng/ll) was determined at an absorbance of 260 nm (A260) using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and was used to calculate the total RNA yield. Total RNA purity was assessed by measuring the A260/280 ratio. Samples with a total RNA yield of at least 1 lg and an A260/ A280 ratio of at least 1.8 were considered of sufficient quality for further analysis. 24 cDNA synthesis and quality assessment Then, 1 mg of total RNA from each patient sample was converted to cDNA using a Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany), using a combination of random hexamer and oligo-dT priming in a 20 ll reaction volume. Before amplifying the gene set using PCR arrays, the quality of each cDNA sample was assessed by measuring the level of HPRT1 expression.
15 HPRT1 is a wellknown reference gene with a low expression level 25 ; therefore, it is suitable for cDNA quality control. To estimate mRNA quality, 1 ll of cDNA was used to amplify the HPRT1 gene in a 10 ll real time PCR reaction using LightCycler 480 SYBR Green I Master (Roche). The specificity of target amplification was confirmed by melting curve analysis. Based on Cq value obtained in the HPRT1 assay, the sample was qualified or not qualified (Cq > 35) for further analysis. 15 
Preamplification
Due to time-dependent fragmentation and the small amount of RNA that can be extracted from FFPE samples, a preliminary RNA amplification step to amplify the RNA without altering the gene expression profiles of the samples is required. 26, 27 In 
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our experience and that of others 27-29 the products of up to 40% of the genes of interest (particularly those with low expression levels) in FFPE samples cannot be detected and reliably quantified using real-time PCR unless the preamplification step is conducted. Therefore, those cDNA samples (n 5 37) that passed HPRT1 quality control underwent preamplification using a RealTime ready cDNA Pre-Amp kit (Roche) according to the manufacturer's instructions. The pre-amplification temperature protocol consisted of 1 min at 958C followed by 14 PCR cycles of denaturation at 958C for 15 sec and annealing/ elongation at 608C for 4 min.
Real-time PCR arrays
Quantitative real-time PCR (qPCR) was performed on a LightCycler 480 II instrument (Roche) with real-time ready custom PCR Arrays (Roche) with pre-plated qPCR assays for 125 genes containing 120 targets and 5 reference genes in triplicate. Each reaction well at 10 ml final volume contained two primers and one Universal ProbeLibrary (UPL) probe, which was a short FAM-labeled hydrolysis probe containing locked nucleic acid (LNA). Special attention was paid to keep amplicons no longer than 100 bp to enhance detection sensitivity and reduce bias in the analysis of fragmented RNA isolated from FFPE tissue. Primers spanning an exon-exon junction were used. Supporting Information TableS1 lists the genes that were analyzed in this study, the primer sequence used for cDNA amplification and the length of the amplified products in base pairs. Quantitative real-time PCR was performed with the following temperature profile: pre-incubation at 958C for 10 min and 45 cycles of amplification consisting of 958C for 10 sec, 608C for 30 sec and 728C for 1 sec.
Analysis of real-time PCR array data and statistical analysis
To identify the most stable reference genes across the study group, RefFinder, a web-based comprehensive tool (http:// fulxie.0fees.us) was used to rank the following analyzed reference genes: GAPDH, RPLP0, SF3A1, B2M, and TBP. GAPDH, RPLP0 and SF3A1 were identified as the most stable reference genes and thus were used for normalization.
RT2 Profiler PCR Array Data analysis web-based software v.3.5 (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis. php), which is dedicated to the analysis of PCR array data, was used. Any Cq value >35 was considered undetected. The DCq for the gene of interest was calculated by subtracting the geometric mean 25 of Cq for GAPDH, RPLP0 and SF3A1 from the Cq for the gene of interest. Differences in expression levels between groups were calculated using the 2 2DDCq method. The P-values were calculated using the two-tailed t test, and P < 0.05 was considered to indicate significance. Fisher's exact test or the v 2 test was used when appropriate to determine differences in categorical variables between the groups. The differences in age distributions between the two groups of patients were analyzed using the t test. The statistical analyses were performed using GraphPad Prism 6 software (San Diego, CA).
Results
A pedigree analysis of 360 patients with TNBC was conducted using the criteria described in the Material and Methods. A hereditary breast cancer was diagnosed in 11.4% (41/360) of these TNBC patients (Fig. 1a) . Testing for germline mutations in BRCA1/2 divided this group in two subgroups, the BRCA1/ 2-associated (30/41 5 73%) and BRCA1/2-negative (11/41 5 27%) subgroups. In the BRCA1/2-associated subgroup of patients with a hereditary TNBC, a germline BRCA1 mutation was identified in 29 of 41 (70.7%) patients, and a germline BRCA2 mutation was identified in only one (2.3%) patient. The remaining 11 TNBC patients, who were negative for germline mutations in BRCA1/2 were screened for large genomic rearrangements in the BRCA1/2 genes using multiplex ligation-dependent probe amplification. No large genomic rearrangements were detected in the BRCA1/2 genes of these patients.
Next, the expression profiles of 120 genes involved in HR and five other DNA damage repair pathways (NER, BER, NHEJ, MMR and FAP) in BRCA1/2-associated and BRCA1/ 2-negative breast cancer subgroups were analyzed using realtime PCR arrays. The expression levels of the vast majority of genes (117/120 5 97.5%) differed by <1.5-fold. A comparison of the results showed no statistically significant differences in the expression levels of the analyzed genes between the two subgroups of hereditary TNBC (Fig. 1b) , indicating the similarity of the two breast cancer subgroups with respect to their DNA damage repair pathways and, therefore, the BRCAness of the BRCA1/2-negative hereditary TNBCs. The two subgroups of hereditary TNBC were also similar with respect to their clinico-pathological characteristics (Table 1) .
Discussion
Strong evidence indicates that the sensitivity of BRCA1/ 2-associated cancers and tumor cell lines to PARP inhibitors or platinum compounds results from incompetent DNA damage repair pathways, particular ineffective HR and NER pathways. 7, 14, 15 Therefore, we assumed that the expression profile of the DNA repair genes in BRCA1/2-associated cancers could be regarded as the gold standard to which any subgroup of breast cancers suspected of BRCAness should be compared. In this study, we determined that BRCA1/2-negative hereditary TNBCs exhibit BRCAness because there were no significant differences in the expression levels of 120 DNA repair genes (including genes involved in HR and NER) between this subgroup and the subgroup of BRCA1/2-associated cancers. The similarity of these two subgroups of hereditary TNBCs was supported by the lack of significant differences in their clinico-pathological characteristics.
Recently much effort has been concentrated on identifying subgroup of TNBCs possessing BRCAness. Various tools and methods have been used to identify BRCAness (thoroughly reviewed in Ref. 13) but there is no current standardized method to detect this property. For example, certain mutation signatures, a gene expression profile associated with the sensitivity to platinum and PARP inhibitors, 30 a specific pattern of genomic copy number aberrations, 10 a BRCA1-like aCGH profile, and BRCA1 promoter methylation 31, 32 are regarded as characteristic of BRCAness. 13 A number of assays to define homologous recombination deficiency have been also reported (reviewed in Ref.
2). BRCAness has been variously defined. According to a recent review, BRCAness "describes the situation in which an homologous recombination repair defect exists in a tumor in the absence of a germline BRCA1 or BRCA2 mutation". 13 Both genetic and epigenetic factors can contribute to the BRCAness phenotype. In short, this phenotype may reflect impaired HR in BRCA1/ 2-negative tumors due to epigenetic BRCA1 promoter hypermethylation, somatic mutations in BRCA1/2 or mutations in genes other than BRCA1/2 that are involved in HR. However, focusing the definition of BRCAness only on incompetent HR appears to be inadequate because defects in other DNA repair pathways, at least in the NHEJ and NER pathways, in which BRCA1 has been implicated (reviewed in Refs. 13 and 14) , may also play a role in this phenotype. Furthermore, complex and extensive crosstalk among DNA repair pathways has been documented in cell lines (reviewed in Ref. 33) and breast cancer core biopsies. 15 Therefore, from the perspective of the response to therapeutics targeting incompetent DNA repair (PARP inhibitors and platinum compounds), whether having incompetent HR is sufficient for a tumor to exhibit BRCAness or whether other DNA repair pathways must also be impaired is currently unknown. However, our results indicate that both subgroups of hereditary TNBCs (BRCA1/2-associated and BRCA1/2-negative) are similar not only with regard to the expression levels of genes involved in HR but also in the expression levels of genes involved in other major DNA damage repair pathways. Thus, even if one broadens the definition of BRCAness to include the existence of defects in DNA repair pathways other than the HR repair pathway, the results of our study indicate that BRCA1/2-negative hereditary TNBCs exhibit BRCAness. DNA damage repair is a complex, multistep process that involves an interacting network of cooperating genes that encode specific proteins that may be involved in various pathways of DNA repair. 34 Therefore, because the DNA repair gene products that are affected by particular therapies are involved in multiple relationships, the closer the similarity in the expression profile of genes engaged in all the major DNA repair pathways to that of BRCA1/2-associated cancers, the stronger the BRCAness of a given tumor may be expected to be.
The prevalence of hereditary breast cancer among TNBCs depends on the criteria applied for determining hereditary origin. In the present study, a TNBC was considered hereditary if there was a history of breast cancer and/or ovarian cancer at any age of diagnosis in at least two of the patient's relatives. 18 Using these criteria, we established the following findings: (i) Approximately 11% of TNBC patients had a strong family history of breast and/or ovarian cancers. (ii) Approximately 73% of all hereditary TNBCs were BRCA1/2-associated. (iii) A total of 27% of the hereditary TNBCs exhibited BRCAness (i.e., had a similar profile of expression of DNA damage repair genes as that of the BRCA1-associated hereditary TNBCs), making this the first study to distinguish a subset of patients with hereditary TNBCs (other than BRCA1/2-associated TNBCs) that are a potential target for therapies directed against incompetent DNA repair pathways, such as PARP inhibitor and platinum-based therapies. The results further suggest that one strategy for choosing candidates likely to benefit from those therapies among the patients with TNBCs is to identify the subset with hereditary TNBCs. Our results showing that BRCA1/2-negative hereditary TNBCs exhibit BRCAness constitute a strong molecular argument for including BRCA1/2-negative patients with hereditary TNBCs in clinical trials of PARP inhibitor and platinum-based therapies. This population is a small, albeit specific subgroup of TNBC patients for whom these treatment methods may be effective. Prospective and retrospective trials to assess whether pathological response to therapy using platinum compounds or PARP inhibitors is similar in the two (BRCA1/2-negative and BRCA1/2-associated) subgroups of patients with hereditary TNBCs are needed to verify the therapeutic significance of our findings. Furthermore, how stringent the criteria for hereditary breast cancer must be to include BRCA1/2-negative hereditary TNBCs in the BRCAness category remains to be established.
In conclusion, our results indicate that BRCA1/2-negative hereditary TNBCs may constitute a target group for therapies 
